Alopecia Areata Universalis during Treatment of Rheumatoid Arthritis with Anti-TNF-&amp;alpha; Antibody (Adalimumab)

Chaves, Yuri Nogueira; Duarte, Gleison Vieira; Bensaïd, Benoît; Tebib, J.; Berard, F.; Nicolas, Jean‐François

doi:10.1159/000162180

Cited by 48 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in larger studies [43,44 ], etancercept and efalizumab were viewed as ineffective in treatment of patients with moderate-tosevere forms of alopecia. Furthermore, patients on etancercept, infliximab, and adalimumab have had recurrences or development of alopecia areata [45][46][47][48], suggesting that tumor necrosis factor (TNF)a may not be essential to the inflammatory pathway of alopecia areata.…”

Section: Other Treatmentsmentioning

confidence: 99%

An update on alopecia areata

Kos

Conlon²

2009

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

Section: Other Treatmentsmentioning

confidence: 99%

An update on alopecia areata

Kos

Conlon²

2009

Current Opinion in Pediatrics

View full text Add to dashboard Cite

show abstract

“…As a result of the study, it was found as ineffective [79]. Several reports have been published indicating the development of AA during a treatment of anti-TNF-α for another disease [80][81][82][83][84][85][86]. Gorcey et al reported a patient with AU, refractory to various treatment modalities, who was successfully treated with adalimumab, while being treated for the flare of atopic dermatitis [87].…”

Section: Tumor Necrosis Factor (Tnf)-α Inhibitorsmentioning

confidence: 96%

New Modalities in the Treatment of Refractory Alopecia Areata

Kılıç¹

2017

Hair and Scalp Disorders

View full text Add to dashboard Cite

Alopecia areata (AA) is a common and complex T-cell-mediated inflammatory disorder. It may be patchy (localized), involve the entire scalp (alopecia totalis) or entire body (alopecia universalis). Alopecia totalis and universalis are often difficult to treat. Although many therapeutic options currently exist in alopecia areata, none of them are curative or preventive. Besides, none of them are approved by Food and Drug Administration (FDA). The disease unfortunately has an unpredictable course. The factors indicating a poor prognosis are the extent of hair loss at the presentation, long duration of the disease, and ophiasis pattern of hair loss. There are only a few randomized controlled studies conducted on recalcitrant AA. Recent research on immunology of hair follicle and recent developments in immunopathogenesis, together with the shared pathways of the disease with other autoimmune disorders, led investigators to focus on novel therapies that target specific immunological pathways. Herein, we will review shortly the current treatment options in recalcitrant alopecia areata based on recently published studies and then will focus on the recently developed broad-spectrum and targeted therapeutics.

show abstract

“…Not only have studies shown this not to be the case [15], alopecia areata has actually been found to occur during treatment with TNF-α inhibitors. The first case was reported in 2004 with the use of infliximab [16] and since then we have identified 34 cases in the literature, including the TNF-α inhibitors adalimumab [4,[17][18][19][20][21][22][23][24][25][26][27], infliximab [16,23,[28][29][30][31][32], and etanercept (Table 1) [4,22,33,34]. In these cases, alopecia areata was diagnosed by both clinical presentation and histopathology, which was available in the majority of cases.…”

Section: Clinical Subtypes Of Alopecia Seen During Treatment With Tnfmentioning

confidence: 99%

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Tosti¹

2014

J Clin Investig Dermatol

View full text Add to dashboard Cite

Background: Alopecia is a possible adverse reaction to Tumor Necrosis Factor alpha (TNF-α) inhibitors. This side effect has become more recognized in recent years through FDA postmarketing surveillance and it description in case reports/case series. Objective:We review the literature and summarize the pathogenesis, clinical presentation, prognosis, and management strategies for TNF-α inhibitor induced alopecia. Methods:We performed a Medline search from January 1998 until August 2013 to identify all cases of alopecia during anti-TNF-α therapy described in the literature. We also reviewed FDA postmarketing data and clinical trials.Results: There were 62 cases of hair loss occurring during therapy with TNF-α inhibitors that we identified during our literature search. The causes of hair loss included alopecia areata, psoriatic alopecia, lichen planopilaris, drug-induced lupus erythematosus, androgenetic alopecia, and telogen effluvium. Alopecia was also a mentioned side effect in three clinical trials and in FDA postmarketing surveillance.Limitations: There are few controlled trials directly studying TNF-α inhibitor induced alopecia and most of our understanding of this clinical condition comes from anecdotal experience.Conclusions: TNF-α inhibitors can cause different types of hair loss including severe alopecia areata and scarring alopecia.

show abstract

Alopecia Areata Universalis during Treatment of Rheumatoid Arthritis with Anti-TNF-α Antibody (Adalimumab)

Cited by 48 publications

References 8 publications

An update on alopecia areata

An update on alopecia areata

New Modalities in the Treatment of Refractory Alopecia Areata

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Contact Info

Product

Resources

About